Project Grant R01CA316276
Award Date 9/1/26
Completion Date 8/31/30
Dollars Obligated $657K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77204, USA
Similar Awards
- The National Cancer Institute awarded The Johns Hopkins University $645,435 on September 2, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop a multimodal blood-based classifier for early hepatocellular carcinoma (HCC) detection. The research integrates genome-wide methods—fragmentomics (DELFI), repeat landscapes (ARTEMIS), methylomics, mutational signatures (GEMINI), and plasma proteomics—into a single machine learning classifier to improve HCC...
- The National Cancer Institute awarded Omicxhealth, Inc. $405,305 on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394, Assistance Listing Project Grant R43CA310377) to develop OMICXSCREEN, an artificial intelligence and machine learning-powered blood test for early detection of hepatocellular carcinoma and esophageal cancer. OMICXSCREEN uses cell-free DNA methylation profiling via whole-genome bisulfite sequencing paired with a patent-pending...
- The National Cancer Institute awarded William Marsh Rice University $385,102 on September 17, 2025, under the Cancer Research Manpower program (CFDA 93.398) to develop a single-cell assay for correlating genotype and phenotype of metastatic cancer cells in vivo using nanolaser optical barcodes. The project addresses technical bottlenecks in understanding metastatic cancer dynamics by developing laser particle technology to create unique optical barcodes enabling real-time tracking of migrating...
- The National Cancer Institute awarded $400,000 to Zeest Bio Inc. on September 15, 2025, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop a novel liver-specific positron emission tomography tracer for improved detection of metastatic tumors and assessment of liver function and biliary tract pathology. The recipient will complete preclinical testing and investigational new drug-enabling studies in preparation for first-in-human clinical trials. Current imaging...
- The National Cancer Institute awarded the University of Texas at Arlington $565,569 under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on June 1, 2026, for the design and synthesis of light-responsive osmium compounds to enable optical image-guided surgery and phototherapy in cancer treatment. The project will develop osmium compounds that luminesce at near-infrared wavelengths where tissue is most transparent, with the compounds engineered to be nontoxic to healthy tissue...
- The National Institutes of Health National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $680,129 on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop drug-loaded degradable biopolymeric scaffolds for augmenting preoperative liver growth. The award funds development of three integrated components: a rat tumor model with cirrhosis background to serve as a clinically translatable animal model; resorbable polymeric scaffolds with...
- The National Cancer Institute awarded The Methodist Hospital Research Institute $830,514 under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on June 9, 2026, as a Project Grant (R21CA299243) for image-guided adaptable CAR T cell therapy development targeting solid tumors. The funded work develops an image-guided, universal adaptable CAR (A-CAR) system to address CAR T cell therapy limitations in solid tumors, including antigen escape, T cell exhaustion, and severe toxicities....
- The National Cancer Institute awarded Simplusdx, Inc. $532,105 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate a point-of-care screening test for hepatocellular carcinoma. Simplusdx will finalize development and clinically translate a point-of-care surveillance test for HCC using the D4 immunoassay platform, a nonfouling poly(oligoethylene glycol methyl ether methacrylate) brush that enables multiplexed, high-sensitivity...
- The National Cancer Institute awarded Baylor University $466,875 under the Cancer Detection and Diagnosis Research program (CFDA 93.394) effective September 1, 2026, to develop a low-cost, label-free optical cavity-based biosensor for point-of-care diagnostics. The project, identified as R15CA313615, will advance detection technology for early identification of cancers, infectious diseases, and cardiovascular diseases by creating a biosensor with enhanced sensitivity using differential detection...
- The National Cancer Institute awarded a cooperative agreement totaling $738,675 to Beckman Research Institute of the City of Hope on March 16, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an exosome-based liquid biopsy assay for non-invasive early detection of colorectal adenomas and cancers. The project addresses the limitation that current fecal immunochemical testing (FIT) shows declining sensitivity for early-stage colorectal cancer and advanced...